Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Cox KL, Essex JW, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: cox kl. Nature. 2023 Feb;614(7948):539-547. doi: 10.1038/s41586-022-05673-2. Epub 2023 Feb 1. Nature. 2023. PMID: 36725933
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS. Roghanian A, et al. Among authors: cox kl. Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005. Cancer Cell. 2015. PMID: 25873171 Free article.
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.
Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS. Tutt AL, et al. Among authors: cox kl. J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28. J Immunol. 2015. PMID: 26512139
Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.
Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH. Turaj AH, et al. Among authors: cox kl. Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub 2017 Nov 30. Cancer Cell. 2017. PMID: 29198913 Free PMC article.
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, Mårtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. Griffiths J, et al. Among authors: cox kl. J Immunother Cancer. 2020 Dec;8(2):e001557. doi: 10.1136/jitc-2020-001557. J Immunother Cancer. 2020. PMID: 33428585 Free PMC article.
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Simpson AP, Roghanian A, Oldham RJ, Chan HTC, Penfold CA, Kim HJ, Inzhelevskaya T, Mockridge CI, Cox KL, Bogdanov YD, James S, Tutt AL, Rycroft D, Morley P, Dahal LN, Teige I, Frendeus B, Beers SA, Cragg MS. Simpson AP, et al. Among authors: cox kl. Cell Rep. 2022 Jul 19;40(3):111099. doi: 10.1016/j.celrep.2022.111099. Cell Rep. 2022. PMID: 35858562 Free PMC article.
277 results